INFLAMMATION AND PSORIASIS: IMMUNOPATHOLOGICAL CHARACTERISTICS AND THERAPEUTIC ADVANCES



Цитировать

Полный текст

Аннотация

Abstract

Psoriasis is a chronic systemic inflammatory disease primarily affecting the skin, characterized by excessive keratinocyte proliferation and T lymphocyte infiltration. This multifactorial condition results from complex interactions between genetic, environmental, and immune factors.
This retrospective study analysed the demographic, clinical, and therapeutic profiles of 136 psoriasis patients admitted to the Internal Medicine and Dermatology departments of the University Hospital Centre of Sidi Bel Abbès (Western Algeria). The cohort showed a balanced sex distribution (50.7% male, 49.3% female) with a mean age of 51.28 ± 14.19 years. The most prevalent forms were erythrodermic (45.8%), vulgaris (32.2%), and pustular (19.2%). The main treatments included corticosteroids (45.6%), topical creams and emollients (27.2%), and immunosuppressants (25%).
Laboratory findings revealed elevated C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR), reflecting chronic systemic inflammation. Patients with high ESR levels also exhibited increased blood glucose, blood pressure, triglycerides, and total cholesterol.
These findings reinforce the systemic nature of psoriasis and highlight the importance of investigating its molecular and immunological mechanisms. They also support the need for comprehensive and personalized management, especially in the context of associated comorbidities such as cardiovascular disease.

Об авторах

meriem rabia Zahzeh Ait Kaci

University of Sidi Bel Abbes, Algeria

Email: rabia.zahzeh@univ-sba.dz
ORCID iD: 0000-0001-6655-0548

PhD in Biology of the Normal and Pathological Cell.

Associate Professor and Head of the Bachelor's Degree in Immunology.

Алжир, Faculty of Natural and Life Sciences, Djillali Liabes University, PO. Box N°89, Sidi Bel Abbes 22000. Algeria

Nesrine Remla

University of Sidi Bel Abbes, Algeria

Email: remla.nesrine@yahoo.fr
ORCID iD: 0000-0001-6859-0973

PhD in Biology of the Normal and Pathological Cell.

Associate Professor

Алжир, Faculty of Natural and Life Sciences, Djillali Liabes University, PO. Box N°89, Sidi Bel Abbes 22000. Algeria

Siheme Ouali

University of Sidi Bel Abbes, Algeria

Email: oualisihem16@gmail.com
ORCID iD: 0000-0002-1767-3397

PhD in Biochemistry and Immunology.

Assistant Professor.

Алжир, Faculty of Natural and Life Sciences, Djillali Liabes University, PO. Box N°89, Sidi Bel Abbes 22000. Algeria

Touria Zahzeh

University of Sidi Bel Abbes, Algeria

Автор, ответственный за переписку.
Email: tzahzeh@yahoo.fr
ORCID iD: 0000-0002-7363-0957

PhD in Nutrition.
Professor of Nutrition. 

Алжир, Faculty of Natural and Life Sciences, Djillali Liabes University, PO. Box N°89, Sidi Bel Abbes 22000. Algeria

Список литературы

  1. Alamri A., Alqahtani R., Alshareef I., Alshehri A., Balkhy A. Psoriasis in Saudi Population: Gender Differences in Clinical Characteristics and Quality of Life. Cureus, 2022, vol. 14, no. 3, p. e22892. https://doi.org/10.7759/cureus.22892
  2. Amador J.R., Becerra-Arias C., Rojas-Zuleta W.G., Castro-Ayarza J.R., Franco M., Barbosa-Rengifo M. Clinical characteristic and outcomes of psoriasis patients in a multicentre outpatient healthcare institution in Colombia. Rev Colomb Reumatol, 2024, vol. 31, p. [in press]. https://doi.org/10.1016/j.rcreu.2024.04.008
  3. Armstrong A.W., Mehta M.D., Schupp C.W., Gondo G.C., Bell S.J., Griffiths C.E.M. Psoriasis Prevalence in Adults in the United States. JAMA Dermatol, 2021, vol. 157, no. 8, pp. 940-946. https://doi.org/10.1001/jamadermatol.2021.2007
  4. Bartlett K.J., Vo A.P., Rueckert J., Wojewoda C., Steckel E.H., Stinnett-Donnelly J., Repp A.B. Promoting appropriate utilisation of laboratory tests for inflammation at an academic medical centre. BMJ Open Qual, 2020, vol. 9, no. 1, p. e000788. https://doi.org/10.1136/bmjoq-2019-000788
  5. Beygi S., Lajevardi V., Abedini R. C-reactive protein in psoriasis: a review of the literature. J Eur Acad Dermatol Venereol, 2014, vol. 28, no. 6, pp. 700-711. https://doi.org/10.1111/jdv.12257
  6. Bronckers I.M.G.J., Paller A.S., van Geel M.J., van de Kerkhof P.C.M., Seyger M.M. Psoriasis in Children and Adolescents: Diagnosis, Management and Comorbidities. Pediatr Drugs, 2015, vol. 17, pp. 373-384. https://doi.org/10.1007/s40272-015-0137-1
  7. Cao L., Lu L., Yu Y., Zhou H., Lin B. Clinical characteristics of patients with a family history of psoriasis: an observational epidemiological study in Chinese Han population. Front Med (Lausanne), 2024, vol. 11, p. 1455953. https://doi.org/10.3389/fmed.2024.1455953
  8. Castro-Ayarza J.R., Barbosa-Rengifo M., Franco-Franco M., Amador J.R., Cárdenas-Rojas P., Becerra-Arias C., Donado-Gómez J., Duque-Zapata N. Biological therapy optimization in patients with psoriasis by reducing the dose or increasing the time interval, in a specialized centre in Colombia. Rev Colomb Reumatol, 2023, vol. 30, Suppl. 1, pp. S65-S69. https://doi.org/10.1016/j.rcreu.2023.02.012
  9. Chodorowska G., Wojnowska D., Juszkiewicz-Borowiec M. C-reactive protein and alpha2-macroglobulin plasma activity in medium-severe and severe psoriasis. J Eur Acad Dermatol Venereol, 2004, vol. 18, no. 2, pp. 180-183. https://doi.org/10.1111/j.1468-3083.2004.00863.x
  10. Gao Y., Xu T., Wang Y., Hu Y., Yin S., Qin Z., Yu H. Pathophysiology and Treatment of Psoriasis: From Clinical Practice to Basic Research. Pharmaceutics, 2025, vol. 17, no. 1, p. 56. https://doi.org/10.3390/pharmaceutics17010056
  11. Gökalp H. Effect of psoriasis severity on inflammation parameters: Controlled study. Turkderm-Turk Arch Dermatol Venereology, 2018, vol. 52, pp. 91-94. https://doi.org/10.4274/turkderm.05025
  12. Griffiths C.E.M., Armstrong A.W., Gudjonsson J.E., Barker J.N.W.N. Psoriasis. Lancet, 2021, vol. 397, no. 10281, pp. 1301-1315. https://doi.org/10.1016/S0140-6736(20)32549-6
  13. Iskandar I.Y.K., Ashcroft D.M., Warren R.B., Lunt M., McElhone K., Smith C.H., Reynolds N.J., Griffiths C.E.M. Comparative effectiveness of biological therapies on improvements in quality of life in patients with psoriasis. Br J Dermatol, 2017, vol. 177, no. 5, pp. 1410-1421. https://doi.org/10.1111/bjd.15531
  14. Jonak C., Göttfried I., Perl-Convalexius S., Gruber B., Schütz-Bergmayr M., Vujic I., Weger W., Schicher N., Semlin L., Hemetsberger M., Cordey M., Sator P. Characteristics and outcomes of patients with psoriasis treated with apremilast in the real-world in Austria - results the APPRECIATE study. Ther Adv Chronic Dis, 2023, vol. 14, p. 20406223231152785. https://doi.org/10.1177/20406223231152785
  15. Kashyap M., Gupta B., Das D. The diagnosis of early psoriatic arthritis in patients of psoriasis visiting dermatology outpatient department. Ip Indian Journal of Clinical and Experimental Dermatology, 2024, vol. 10, no. 3, pp. 266-270. https://doi.org/10.18231/j.ijced.2024.047
  16. Kim W.B., Jerome D., Yeung J. Diagnosis and management of psoriasis. Can Fam Physician, 2017, vol. 63, no. 4, pp. 278-285. https://pubmed.ncbi.nlm.nih.gov/28404701/
  17. Kim Y.H., Kim S.I., Park B., Lee E.S. Clinical Characteristics of Psoriasis for Initiation of Biologic Therapy: A Cluster Analysis. Ann Dermatol, 2023, vol. 35, no. 2, pp. 132-139. https://doi.org/10.5021/ad.22.148
  18. Kimak-Pielas A., Robak E., Zajdel R., Zebrowska A. Demographics, Disease Characteristics, and Treatment patterns of patients with plaque psoriasis Treated with Biological Drugs: The Experience of a Single-Centre Study in Poland. J Clin Med, 2024, vol. 13, p. 7647. https://doi.org/10.3390/jcm13247647
  19. Korman N.J. Management of psoriasis as a systemic disease: what is the evidence? Br J Dermatol, 2020, vol. 182, no. 4, pp. 840-848. https://doi.org/10.1111/bjd.18245
  20. Kustán P., Kőszegi T., Miseta A., Péter I., Ajtay Z., Kiss I., Németh B. Urinary Orosomucoid: A potential Marker of Inflammation in psoriasis. Int J Med Sci, 2018, vol. 15, no. 11, pp. 1113-1117. https://doi.org/10.7150/ijms.25687
  21. Luan Y.Y., Yao Y.M. The Clinical Significance and Potential Role of C-Reactive Protein in Chronic Inflammatory and Neurodegenerative Diseases. Front Immunol, 2018, vol. 9, p. 1302. https://doi.org/10.3389/fimmu.2018.01302
  22. Majid A., Fouad M. Serum visfatin, resistin levels and inflammation markers in psoriasis. Ukr Biochem J, 2022, vol. 94, no. 6, pp. 48-56. https://doi.org/10.15407/ubj94.06.048
  23. Malatestinic W., Nordstrom B., Wu J.J., Goldblum O., Solotkin K., Lin C.Y., Kistler K., Fraeman K., Johnston J., Hawley L.L., Sicignano N., Araujo A. Characteristics and Medication Use of Psoriasis Patients Who May or May Not Qualify for Randomized Controlled Trials. J Manag Care Spec Pharm, 2017, vol. 23, no. 3, pp. 370-381. https://doi.org/10.18553/jmcp.2017.16367
  24. Metin Z., Tur K., Durmaz K., Akogul S., Akca H.M., Imren I.G., Demir N.B.O., Ozkoca D. A comprehensive investigation of novel and traditional inflammatory and metabolic markers as predictive indicators in psoriasis. Int J Dermatol, 2023, vol. 62, no. 10, pp. 1272-1280. https://doi.org/10.1111/ijd.16813
  25. Parisi R., Iskandar I.Y.K., Kontopantelis E., Augustin M., Griffiths C.E.M., Ashcroft D.M. National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study. BMJ, 2020, vol. 369, p. m1590. https://doi.org/10.1136/bmj.m1590
  26. Petit R.G., Cano A., Ortiz A., Espina M., Prat J., Muñoz M., Severino P., Souto E.B., García M.L., Pujol M., Sánchez-López E. Psoriasis: From Pathogenesis to Pharmacological and Nano-Technological-Based Therapeutics. Int J Mol Sci, 2021, vol. 22, no. 9, p. 4983. https://doi.org/10.3390/ijms22094983
  27. Raharja A., Mahil S.K., Barker J.N. Psoriasis: a brief overview. Clin Med (Lond), 2021, vol. 21, no. 3, pp. 170-173. https://doi.org/10.7861/clinmed.2021-0257
  28. Rahman P., Elder J.T. Genetic epidemiology of psoriasis and psoriatic arthritis. Ann Rheum Dis, 2005, vol. 64, Suppl. 2, pp. ii37-ii39. https://doi.org/10.1136/ard.2004.030775
  29. Rendon A., Schäkel K. Psoriasis Pathogenesis and Treatment. Int J Mol Sci, 2019, vol. 20, no. 6, p. 1475. https://doi.org/10.3390/ijms20061475
  30. Tan M., Luo Y., Hu J., Hu K., Li X., Yang J., Chen J., Zhu W., Kuang Y. Elevated C-Reactive Protein and Erythrocyte Sedimentation Rate Correlates with Depression in Psoriasis: A Chinese Cross-Sectional Study. Clin Cosmet Investig Dermatol, 2023, vol. 16, pp. 397-405. https://doi.org/10.2147/CCID.S401934
  31. Wu B., Chen Q., Cao R., Zhu L., Zhu H. Comparative effectiveness of combined biologic agents versus standard therapies in the treatment of plaque psoriasis: a retrospective analysis. Front Med (Lausanne), 2024, vol. 11, p. 1451069. https://doi.org/10.3389/fmed.2024.1451069

Дополнительные файлы

Доп. файлы
Действие
1. JATS XML
Скачать

© ZAHZEH AIT KACI m., REMLA N., OUALI S., ZAHZEH T.,

Creative Commons License
Эта статья доступна по лицензии Creative Commons Attribution 4.0 International License.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № 77 - 11525 от 04.01.2002.


Данный сайт использует cookie-файлы

Продолжая использовать наш сайт, вы даете согласие на обработку файлов cookie, которые обеспечивают правильную работу сайта.

О куки-файлах